

# Shan He

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6491115/publications.pdf>

Version: 2024-02-01

30  
papers

873  
citations

471509

17  
h-index

677142

22  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1645  
citing authors

#	ARTICLE	IF	CITATIONS
1	miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate. <i>Nature Communications</i> , 2019, 10, 2157.	12.8	55
2	Artesunate Inhibits Graft-Versus-Host Disease in Mice Via a Mechanism of Inducing Mitochondrial Calcium Overloading in Activated T Cells. <i>Blood</i> , 2019, 134, 4432-4432.	1.4	1
3	Stim1 Deletion Synthetically Rescues Ezh2-Null Effector T Cells and Alloimmunity. <i>Blood</i> , 2018, 132, 4533-4533.	1.4	0
4	Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model. <i>Blood</i> , 2018, 132, 2050-2050.	1.4	1
5	Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice. <i>Blood</i> , 2017, 129, 2737-2748.	1.4	31
6	Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity. <i>Nature Communications</i> , 2017, 8, 2125.	12.8	99
7	Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis. <i>Frontiers in Oncology</i> , 2016, 6, 211.	2.8	7
8	Programming of donor T cells using allogeneic $\delta$ -like ligand 4 <sup>+</sup> positive dendritic cells to reduce GVHD in mice. <i>Blood</i> , 2016, 127, 3270-3280.	1.4	22
9	DLL4+ dendritic cells: Key regulators of Notch Signaling in effector T cell responses. <i>Pharmacological Research</i> , 2016, 113, 449-457.	7.1	24
10	The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation. <i>Journal of Immunology</i> , 2016, 196, 1070-1080.	0.8	53
11	MLL Histone Methyltransferase Restrains Effector Differentiation and PD-1 Expression in Human CD8+ T Cells While Promoting Their Proliferation. <i>Blood</i> , 2016, 128, 863-863.	1.4	0
12	The Notch Ligand DLL4 Derived from Human Dendritic Cells Is Critical for Promoting T Helper (Th)1 and Th17 Cell Differentiation. <i>Blood</i> , 2015, 126, 3431-3431.	1.4	0
13	Programming of Donor T Cells Using Allogeneic Delta-like Ligand 4-Positive Dendritic Cells to Reduce Gvhd but Retain GVL Activity. <i>Blood</i> , 2015, 126, 233-233.	1.4	25
14	Pharmacological Inhibition of Hsp90 Destabilizes the Histone Methyltransferase Ezh2 in Alloreactive T Cells and Reduces Graft-Versus-Host Disease While Retaining Anti-Leukemic Effects in Mice. <i>Blood</i> , 2015, 126, 234-234.	1.4	0
15	Ezh2 Regulates Transcriptional and Posttranslational Expression of T-bet and Promotes Th1 Cell Responses Mediating Aplastic Anemia in Mice. <i>Journal of Immunology</i> , 2014, 192, 5012-5022.	0.8	57
16	The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease. <i>Blood</i> , 2013, 122, 4119-4128.	1.4	54
17	Delta-like Ligand 4 Identifies a Previously Uncharacterized Population of Inflammatory Dendritic Cells That Plays Important Roles in Eliciting Allogeneic T Cell Responses in Mice. <i>Journal of Immunology</i> , 2013, 190, 3772-3782.	0.8	44
18	Histone methyltransferase and histone methylation in inflammatory T-cell responses. <i>Immunotherapy</i> , 2013, 5, 989-1004.	2.0	32

#	ARTICLE	IF	CITATIONS
19	The Histone Methyltransferase Ezh2 Is a Crucial Epigenetic Regulator Of Allogeneic T Cell Responses and Graft-Versus-Host Disease In Mice. <i>Blood</i> , 2013, 122, 137-137.	1.4	0
20	The Epigenetic Regulator Ezh2 Is An Effective Target For Controlling Th1 Cell-Mediated Acquired Aplastic Anemia In Mice. <i>Blood</i> , 2013, 122, 2467-2467.	1.4	4
21	Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. <i>Blood</i> , 2012, 119, 1274-1282.	1.4	70
22	Identification of Previously Uncharacterized Delta 4-Positive Inflammatory Plasmacytoid Dendritic Cells That Play Important Roles in Eliciting Graft-Versus-Host Disease in Mice. <i>Blood</i> , 2012, 120, 337-337.	1.4	1
23	Histone Methyltransferase Ezh2 Controls T-Cell Immunity by Regulating Bioenergetic Metabolism. <i>Blood</i> , 2012, 120, 953-953.	1.4	0
24	Notch and inflammatory T-cell response: new developments and challenges. <i>Immunotherapy</i> , 2011, 3, 1353-1366.	2.0	17
25	Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. <i>Blood</i> , 2011, 117, 299-308.	1.4	114
26	Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease. <i>Blood</i> , 2011, 117, 1723-1733.	1.4	33
27	Characterization of the Metabolic Phenotype of Rapamycin-Treated CD8+ T Cells with Augmented Ability to Generate Long-Lasting Memory Cells. <i>PLoS ONE</i> , 2011, 6, e20107.	2.5	56
28	Inhibition of Histone Methylation Arrests Ongoing Graft-Versus-Host Diseases in Mice by Selectively Inducing Apoptosis of Alloreactive Effector T Cells. <i>Blood</i> , 2011, 118, 820-820.	1.4	0
29	A New Approach to the Blocking of Alloreactive T Cell-Mediated Graft-versus-Host Disease by In Vivo Administration of Anti-CXCR3 Neutralizing Antibody. <i>Journal of Immunology</i> , 2008, 181, 7581-7592.	0.8	56
30	MIP-3 $\beta$ and MIP-1 $\beta$ rapidly mobilize dendritic cell precursors into the peripheral blood. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1549-1556.	3.3	17